Skip to main content

Diabetes Mellitus, Insulin-Dependent, 1 clinical trials at UCSF
1 in progress, 0 open to new patients

  • Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

    Sorry, in progress, not accepting new patients

    Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia with current technology, and thus they are at risk for devastating long-term complications. This phase II study is designed to evaluate the safety and efficacy of imatinib mesylate as a novel therapy for new-onset T1DM. Imatinib is a first-in-class tyrosine kinase inhibitor. This study will explore the potential role of short-term therapy with imatinib to induce tolerance and possibly lead to a durable long-term remission of T1DM.

    San Francisco, California and other locations